Why thyroid cancer trial monitoring is important in 2026
Thyroid cancer is the most common endocrine malignancy, with over 43,000 new cases diagnosed annually in the United States. While most well-differentiated thyroid cancers are curable with surgery and radioiodine, a significant subset of patients progress to radioiodine-refractory (RAIR) differentiated thyroid cancer, medullary thyroid cancer (MTC), or the rapidly lethal anaplastic thyroid cancer (ATC), all representing active clinical development areas.
The thyroid cancer pipeline in 2026 is one of the most molecularly precise in oncology:
- RET inhibitors: selpercatinib (Retevmo) and pralsetinib (Gavreto) transformed RET-mutant MTC and RET-fusion thyroid cancer. Next-generation RET programs targeting acquired resistance are entering trials
- BRAF V600E inhibitors: dabrafenib/trametinib is approved for BRAF-mutant ATC; combination strategies expanding across DTC subtypes
- NTRK inhibitors: larotrectinib and entrectinib for NTRK-fusion thyroid cancer; resistance mechanisms under study
- Radioiodine redifferentiation: BRAF or MEK inhibition to restore radioiodine uptake in RAIR DTC is an active Phase 2 space
- Immunotherapy in ATC: pembrolizumab-based combinations showing activity in ATC; multiple programs ongoing
- Lenvatinib combinations: beyond the approved monotherapy setting, lenvatinib paired with IO is being explored across subtypes
Track every new thyroid cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it and delivers a clean digest every morning.
Start Free: No Credit CardA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| The Application of Electrical Stimulation in Postoperative Pain Management of… NCT06931743 | Primary completion moved at least 12 months later Primary endpoint removed | Recruiting |
26 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Laser Ablation of Papillary Thyroid Microcarcinoma NCT04623801 | Oct 2026 · Estimated | Phase 2 |
9 more on the Completions page. See the calendar →
What we monitor for thyroid cancer
Our system pulls from the ClinicalTrials.gov API every day. For a thyroid cancer watch profile, you can configure a saved search for:
- Condition keywords: "thyroid cancer", "differentiated thyroid cancer", "papillary thyroid cancer", "medullary thyroid cancer", "anaplastic thyroid cancer", "follicular thyroid cancer"
- Drug/target keywords: "RET", "selpercatinib", "BRAF thyroid", "lenvatinib", "sorafenib", "cabozantinib", "radioiodine refractory", any drug or target you're tracking
- Phase filter: Phase 1 for early competitive intelligence, Phase 2/3 for clinically meaningful competitive threats
- Sponsor type: Industry, academic, or all sponsors
- Status changes: New registrations, status updates, enrollment completions, and results postings
The molecularly-driven thyroid cancer pipeline
Thyroid cancer has become a showcase for precision oncology. The dominant oncogenic drivers, RET fusions/mutations, BRAF V600E, RAS mutations, NTRK fusions, are each targetable with approved or investigational agents. This creates a complex competitive landscape where multiple targeted agents compete across subtypes:
- MTC: RET-mutant MTC is now a required biomarker screen. Vandetanib and cabozantinib remain approved options; selpercatinib and pralsetinib have superior selectivity. Next-gen RET inhibitors in development include compounds targeting C481S and other resistance mutations
- RAIR DTC: Lenvatinib and sorafenib approved; multiple Phase 2 redifferentiation strategies (using BRAF, MEK, or PI3K inhibitors) aimed at restoring radioiodine sensitivity, this is an active and underserved space
- ATC: BRAF V600E-mutant ATC (approximately 45% of cases) can respond dramatically to dabrafenib+trametinib; IO combinations are the major active area for BRAF wild-type ATC
Who uses thyroid cancer trial monitoring
- Endocrine oncology BD teams: tracking competitor programs targeting RET, BRAF, NTRK for partnering or pipeline decisions
- Oncology investors: monitoring Phase 1/2 initiations for precision thyroid cancer programs
- Thyroid cancer patient advocacy groups: tracking new trial options for patients with advanced or refractory disease
- Endocrinologists and head-and-neck oncologists: staying current on available trials for RAIR DTC and MTC patients
- Academic researchers: monitoring competitive landscape and identifying collaboration opportunities
Stop missing new thyroid cancer trials
Set up your digest in 2 minutes. Daily digest to your inbox. Cancel anytime.
Track Free Thyroid Cancer Trials334 active trials, 178 recruiting.
Industry sponsors run 44 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 30.
| Top industry sponsor | Active trials |
|---|---|
| Eli Lilly and Company | 5 |
| Exelixis | 4 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 |
| Novartis Pharmaceuticals | 3 |
| Novo Nordisk | 2 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Real-World Study of Second-line Therapies Among Radioiodine-refractory… NCT07770074 | Not Yet Recruiting | Study completion pushed from Oct 31, 2026 to Jan 5, 2027 | 2026-10-16 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced… NCT06239194 | Recruiting | Enrollment increased: 285 → 330 participants | 2026-10-16 |
| Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of… NCT07529080 | Not Yet Recruiting | Study completion pushed from Aug 2027 to Dec 2027 | 2026-10-16 |
| Agnostic Therapy in Rare Solid Tumors NCT06638931 | Active, Not Recruiting | Primary completion pushed from Jul 2026 to Jul 2027 | 2026-10-14 |
| Thyroid Nodule Gene Sequencing in a Danish Population NCT05377736 | Active, Not Recruiting | Study completion pushed from Jan 18, 2027 to Jan 18, 2028 | 2026-10-10 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.